Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

The Oncologist(2018)10.1634/theoncologist.2018-0028Source: DataRank Database

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome is a research paper published in The Oncologist (2018). On theSindex it has a DataRank of 1.0. It has been cited 896 times.

N/A

1.0DataRank · unranked

Scored on demand from live citation data

896 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 40.30)OA: hybridTopics (52)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

1.0

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (9)

Liang Li ORCID,Weishi Yuan,Stacy S. Shord ORCID,Lei Nie ORCID,Bahru A. Habtemariam

Live enrichment

PubMed:29622697 PMC:PMC6156173 OpenAlex:https://openalex.org/W2796022095

FWCI

40.30

Citation Percentile

1.0%

Citation Trend

2018

2019

2020

2021

2022

2023

2024

2025

2026

hybridLicense: public-domain

journalhttps://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0028

publisherhttps://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0028

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2018-0028

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2018-0028

publisherhttps://academic.oup.com/oncolo/article-pdf/23/8/943/41915430/oncolo_23_8_943.pdf

Fields of Study

CAR-T cell therapy researchAutoimmune and Inflammatory Disorders ResearchCancer Immunotherapy and BiomarkersAdolescentAdultAntibodies, Monoclonal, HumanizedChildChild, PreschoolCytokinesFemaleHumansMaleProspective StudiesReceptors, Antigen, T-CellReceptors, Chimeric AntigenRetrospective StudiesSyndromeUnited StatesUnited States Food and Drug AdministrationYoung Adult

MeSH Terms

Receptors, Chimeric AntigenAdolescentAdultChildChild, PreschoolFemaleHumansMaleProspective StudiesReceptors, Antigen, T-CellRetrospective StudiesSyndromeUnited StatesUnited States Food and Drug AdministrationCytokinesYoung AdultAntibodies, Monoclonal, Humanized

Keywords

TocilizumabMedicineCytokine release syndromeInternal medicinePopulationConfidence intervalAdverse effectRetrospective cohort studyChimeric antigen receptorSurgeryCancerImmunotherapyDiseaseT cellInterleukin‐6

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

10.6084/m9.figshare.13126376.v1figshare

Additional file 1 of Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

10.6084/m9.figshare.13126376figshare

Additional file 1 of Effects of Tocilizumab in COVID-19 patients: a cohort study

10.6084/m9.figshare.13481069.v1figshare

Additional file 1 of Effects of Tocilizumab in COVID-19 patients: a cohort study

10.6084/m9.figshare.13481069figshare

Additional file 1 of Systemic interleukin-6 inhibition ameliorates acute neuropsychiatric phenotypes in a murine model of acute lung injury

10.6084/m9.figshare.21099112.v1figshare

Additional file 1 of Systemic interleukin-6 inhibition ameliorates acute neuropsychiatric phenotypes in a murine model of acute lung injury

10.6084/m9.figshare.21099112figshare

Additional file 1 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554517.v1figshare

Additional file 1 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554517figshare

Additional file 2 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554520.v1figshare

Additional file 2 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554520figshare

Additional file 4 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554526.v1figshare

Additional file 4 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554526figshare

Additional file 5 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554529.v1figshare

Additional file 5 of Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

10.6084/m9.figshare.26554529figshare

Additional file 1 of Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

10.6084/m9.figshare.26665123.v1figshare

Additional file 2 of Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

10.6084/m9.figshare.26665126.v1figshare

Additional file 1 of Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

10.6084/m9.figshare.26665123figshare

Additional file 2 of Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

10.6084/m9.figshare.26665126figshare

Additional file 3 of Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

10.6084/m9.figshare.26665129.v1figshare

Additional file 3 of Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review

10.6084/m9.figshare.26665129figshare

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

FAIR Checklist

DataRank Breakdown

Authors (9)

Impact

Open Access

Topics

Linked Datasets (25)